Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3814-3825

  Havrilesky, Laura ^a   Darcy, Kathleen M ^a   Hamdan, Hasnah ^a   Priore, Roger L ^a   Leon, Jorge ^a   Bell, Jeffrey ^a   Berchuck, Andrew ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0142087616     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.052     Document Type: Article

References (62)

1. Berchuck A, Kohler MF, Marks JR, et al: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246-252, 1994
2. Hainaut P, Hernandez T, Robinson A, et al: IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26:205-213, 1998
3. Wang XW, Harris CC: p53 tumor-suppressor gene: Clues to molecular carcinogenesis. J Cell Physiol 173:247-255, 1997
4. Shahin MS, Hughes JH, Sood AK, et al: The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89:2006-2017, 2000
5. Oren M, Rotter V: Introduction: p53-The first twenty years. Cell Mol Life Sci 55:9-11, 1999
6. Asker C, Winman KG, Selivanova, G: p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 265:1-6, 1999
7. Bennett MR: Mechanisms of p53-induced apoptosis. Biochem Pharm 58:1089-1095, 1999
8. Yamasaki L: Balancing proliferation and apoptosis in vivo: The Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1423:M9-M15, 1999
9. Bates S, Vousden KH: Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37, 1999
10. Sionov RV, Haupt Y: The cellular response to p53: The decision between life and death. Oncogene 18:6145-6157, 1999
11. Sheikh MS, Fornace AJ Jr: Role of p53 family members in apoptosis. J Cell Physiol 182:171-181, 2000
12. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989
13. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
14. Albrechtsen N, Dornreiter I, Grosse F, et al: Maintenance of genomic integrity by p53: Complementary roles for activated and non-activated p53. Oncogene 18:7706-7717, 1999
15. Janus F, Albrechtsen N, Dornreiter I, et al: The dual role of p53 in maintaining genomic integrity. Cell Mol Life Sci 55:12-27, 1999
16. May P, May E: Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 18:7621-7636, 1999
17. Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96-107, 1999
18. Ashcroft M, Vousden KH: Regulation of p53 stability. Oncogene 18:7637-7643, 1999
19. Meek DW: Mechanisms of switching on p53: A role for covalent modification? Oncogene 18:7666-7675, 1999
20. Weinstein JN, Myers TG, O'Conner PM, et al: An information-intensive approach to molecular pharmacology of cancer. Science 275:343-349, 1997
21. Hartmann L, Podratz K, Keeney G, et al: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69, 1994
22. Schildkraut JM, Halabi S, Bastos E, et al: Prognostic factors in early-onset epithelial ovarian cancer: A population-based study. Obstet Gynecol 95:119-127, 2000
23. van der Zee AGJ, Hollema H, Suurmeijer AJ, et al: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
24. Berns EM, Klijn JG, van PWL, et al: JA. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 16:121-127, 1998
25. Geisler JP, Geisler HE, Wiemann MC, et al: Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66:435-438, 1997
26. Eltabbakh GH, Belinson JL, Kennedy AW, et al: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80:892-898, 1997
27. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129-4133, 1993
28. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
29. Brown R, Clugston C, Burns P, et al: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678-684, 1993
30. Herod JJ, Eliopoulos AG, Warwick J, et al: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184, 1996
31. Eliopoulos AG, Kerr DJ, Herod J, et al: The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11:1217-1228, 1995
32. Righetti SC, Della TG, Pilotti S, et al: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693, 1996
33. Perego P, Giarola M, Righetti SC, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562, 1996
34. Sjorgen S, Inganas M, Norberg T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
35. Borresen AL, Andersen TI, Eyfjord JE, et al: TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14:71-75, 1995
36. Reles A, Wen WH, Schmider A, et al: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984-2997, 2001
37. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
38. Kohler MF, Kerns BJ, Humphrey PA, et al: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643-650, 1993
39. Casey G, Lopez ME, Ramos JC, et al: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981, 1996
40. Skilling JS, Sood A, Niemann T, et al: An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13:117-123, 1996
41. Marks JR, Davidoff AM, Kerns BJ, et al: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991
42. Agresti A: Categorical Data Analysis. New York, NY, John Wiley & Sons, Inc, 1990, pp 42-43, 60-61
43. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583-621, 1952
44. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
45. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
46. Cox DR: Regression models and life tables. J Royal Stat Soc 34:187-220, 1972
47. Hosmer DW, Lemeshow S: Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY, John Wiley & Sons, Inc, 1999, pp 93-105, 158-195, 205-216
48. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer, 1997, pp 251-259
49. Salvat C, Aquaviva C, Jariel-Encontre I, et al: Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 degradation in vivo? Mol Biol Rep 26:45-51, 1999
50. Yap DBS, Hsieh J-K, Chan FSG, et al: mdm2: A bridge over the two tumor suppressors, p53 and Rb. Oncogene 18:7681-7689, 1999
51. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
52. Somasundaram K, MacLachlan TK, Burns TF, et al: BRCA1 signals ARF-dependent station and coactivation of p53. Oncogene 18:6605-6614, 1999
53. Sheih S-Y, Ikeda M, Taya Y, et al: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334, 1997
54. Lain S, Xirodimas D, Lane DP: Accumulating active p53 in the nucleus by inhibition of nuclear export: A novel strategy to promote the p53 tumor suppressor function. Exp Cell Res 253:315-324, 1999
55. Havrilesky LJ, Elbendary A, Hurteau JA, et al: Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85:1007-1010, 1995
56. Lavarino C, Pilotti S, Oggionni M, et al: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936-3945, 2000
57. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al: Tp53 mutation and p53 overexpression in prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56, 2000
58. Borresen-Dale AL, Lothe RA, Meling GI, et al: TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210, 1998
59. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of the p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
60. Quinlan DC, Davidson AD, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
61. Yamaguchi A, Kurosaka Y, Fushida S, et al: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784, 1992
62. Gray RJ: Flexible methods for aning survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942-951, 1992